摘要
目的观察参一胶囊联合盐酸厄洛替尼片及紫杉醇治疗肺癌的临床效果。方法选取2022年12月—2024年1月于福建省龙岩人民医院接受治疗的肺癌患者110例,按照随机数字表法分为参一胶囊联合组(n=55)和常规两药联合组(n=55),参一胶囊联合组采用参一胶囊联合盐酸厄洛替尼片及紫杉醇治疗,常规两药联合组采用盐酸厄洛替尼片及紫杉醇治疗,2组均治疗4个疗程。比较2组近期疗效,治疗前后肿瘤标志物[癌胚抗原(CEA)、中性粒细胞胞外诱捕网(NETs)、增殖细胞核抗原(PCNA)]、免疫功能指标[自然杀伤细胞(NK)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)]、肺癌患者生存质量测定量表(FACT-L)评分,不良反应。结果参一胶囊联合组客观缓解率为76.36%,高于常规两药联合组的58.18%(χ^(2)=4.129,P=0.042)。治疗4个疗程后,2组血清CEA、NETs、PCNA水平低于治疗前,且参一胶囊联合组低于常规两药联合组(P<0.01);2组血清NK、IgA、IgG水平高于治疗前,且参一胶囊联合组高于常规两药联合组(P<0.05或P<0.01);2组各项FACT-L评分高于治疗前,且参一胶囊联合组高于常规两药联合组(P<0.01)。参一胶囊联合组与常规两药联合组不良反应总发生率比较差异无统计学意义(10.91%vs.7.27%,χ^(2)=0.440,P=0.507)。结论参一胶囊联合盐酸厄洛替尼片及紫杉醇治疗肺癌可改善患者临床症状,降低肿瘤标志物水平,提高免疫功能及生存质量,且安全性较高。
Objective To observe the clinical effect of Shenyi capsules combined with erlotinib hydrochloride tablets and paclitaxel in the treatment of lung cancer.Methods A total of 110 lung cancer patients treated in Longyan People′s Hospital of Fujian from December 2022 to January 2024 were selected and divided into Shenyi capsules combination group(n=55)and conventional two-drug combination group(n=55)according to random number table method.Shenyi capsules combination group was treated with Shenyi capsules combined with erlotinib hydrochloride tablets and paclitaxel,conventional two-drug combination group was treated with erlotinib hydrochloride tablets and paclitaxel,both groups were treated for 4 courses.The short-term efficacyas,tumor markers(CEA,NETs,PCNA),immune function indicators(NK,IgA,IgG)and FACT-L score before and after treatment,adverse reactions of the two groups were compared.Results The objective remission rate of Shenyi capsules combination group was 76.36%,which was higher than that of conventional two-drug combination group(58.18%)(χ^(2)=4.129,P=0.042).After 4 courses of treatment,serum CEA,NETs and PCNA levels in 2 groups were lower than before treatment,and Shenyi capsules combination group was lower than conventional two-drug combination group(P<0.01).Serum NK,IgA and IgG levels in two groups were higher than before treatment,and Shenyi capsules combination group was higher than conventional two-drug combination group(P<0.05 or P<0.01).The FACT-L scores in two groups were higher than before treatment,and the Shenyi capsules combination group was higher than the conventional two-drug combination group(P<0.01).There was no significant difference in the incidence of adverse reactions between the Shenyi capsules combination group and the conventional two-drug combination group(10.91%vs.7.27%,χ^(2)=0.440,P=0.507).Co nclusion Shenyi capsules combined with erlotinib hydrochloride tablets and paclitaxel in the treatment of lung cancer can improve the clinical symptoms of patients,reduce the level of tumor markers,improve immune function and quality of life,and have high safety.
作者
许晓凤
阙丽梅
麻益龙
XU Xiaofeng;QUE Limei;MA Yilong(Department of Respiratory Medicine,Longyan People′s Hospital of Fujian,F ujian Province,Longyan 364000,China)
出处
《临床合理用药》
2025年第17期12-15,共4页
Chinese Journal of Clinical Rational Drug Use
基金
龙岩市科技计划项目(2023LYF17011)。
关键词
肺癌
参一胶囊
盐酸厄洛替尼片
紫杉醇
肿瘤标志物
Lung cancer
Shenyi capsules
Erlotinib hydrochloride tablets
Paclitaxel
Tumor marker
